🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million new cases annually. Particularly high rates are reported in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Results and Global Access

According to data detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses an injection and a pill. The study included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced optimism. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.